Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma
Kim, T.M., Taszner, M., Novelli, S., Cho, S-G., Villasboas, J.C., Merli, M., Jiménez-Ubieto, A., Tessoulin, B., Poon, L.M., Tucker, D., Walewski, J., Yi, S., Song, Y., Chong, G., Bachy, E., Guidez, S., Alonso, A., Jagadeesh, D., Zhang, W., Magnano, L., Iskierka-Jażdżewska, E., Tani, M., Shen, B., Uppala, A., Zhu, M., Shariff, S., Brouwer-Visser, J., Chaudhry, A., Mohamed, H., Ambati, S., Luminari, S.
Published in Annals of oncology (01.11.2024)
Published in Annals of oncology (01.11.2024)
Get full text
Journal Article
CLINICAL RESPONSES TO ODRONEXTAMAB (REGN1979): CORRELATION WITH LOSS OF CD20 EXPRESSION AS A POTENTIAL MECHANISM OF RESISTANCE AND BASELINE BIOMARKERS OF TUMOR T CELLS
Brouwer‐Visser, J, Fiaschi, N, Deering, R. P, Dhanik, A, Cygan, K. J, Zhang, W, Jeong, S, Pourpe, S, Boucher, L, Hamon, S, Topp, M. S, Bannerji, R, Duell, J, Advani, R. H, Flink, D. M, Chaudhry, A, Sirulnik, A, Lowy, I, Murphy, A. J, Weinreich, D. M, Yancopoulos, G. D, Thurston, G, Ambati, S. R, Jankovic, V
Published in Hematological oncology (01.06.2021)
Published in Hematological oncology (01.06.2021)
Get full text
Journal Article
Evaluation of a novel combination treatment strategy using patient-derived xenografts of uterine carcinosarcoma
Brouwer-Visser, J, Mi, S, Cossio, M, Schwartz, M.A, Hebert, T, Zou, Y, Kuo, D.Y.S
Published in Gynecologic oncology (01.04.2015)
Published in Gynecologic oncology (01.04.2015)
Get full text
Journal Article
Subcellular localization and function of insulin-like growth factor 2 (IGF2) in uterine carcinosarcoma
Heim, J.A, Mi, S, Cossio-Poblete, M, Brouwer-Visser, J, Wang, Y, Gunter, M.J
Published in Gynecologic oncology (01.06.2014)
Published in Gynecologic oncology (01.06.2014)
Get full text
Journal Article
BET INHIBITOR RG6146, VENETOCLAX, AND RITUXIMAB IS A HIGHLY ACTIVE REGIMEN IN RELAPSED/REFRACTORY (R/R) DLBCL: INITIAL REPORT OF PHASE 1B SAFETY, BIOMARKER, AND RESPONSE DATA
Dickinson, M., Briones Mejjide, J., Herrera, A.F., González Barca, E., Ghosh, N., Cordoba, R., Rutherford, S.C., Advani, R., Bournazou, E., Labriola‐Tompkins, E., Friess, T., Chesne, E., Brouwer‐Visser, J., Lechner, K., Brennan, B., Nueesch, E., De Mario, M., Hutchings, M.
Published in Hematological oncology (01.06.2019)
Published in Hematological oncology (01.06.2019)
Get full text
Journal Article
754P Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study
O'Cearbhaill, R.E., Moore, K.N., Yeku, O., Liu, J.F., Bouberhan, S., Hamilton, E.P., Hou, J.Y., Van Nieuwenhuysen, E., Papadimitriou, K., Yoo, S-Y., Govindraj, S., Brouwer-Visser, J., Peterman, M., Schmidt, T., Barnes, B., Madia, P., Zhu, M., Uldrick, T.S., Miller, E.A., O'Malley, D.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
523MO Ubamatamab (REGN4018, MUC16xCD3 bispecific antibody) monotherapy in patients with recurrent ovarian cancer (OC): Phase I dose-escalation analysis
Van Nieuwenhuysen, E., O'Malley, D., O'Cearbhaill, R.E., Moore, K.N., Hamilton, E.P., Yeku, O., Bouberhan, S., Hou, J.Y., Yoo, S-Y., Brouwer-Visser, J., Cheung, H.K., Peterman, M., Goncalves, P., Schmidt, T., Zhu, M., Lowy, I., Rowlands, T., Uldrick, T.S., Miller, E.A., Liu, J.F.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
127P REGN5668 (MUC16xCD28 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study
Winer, I.S., O'Cearbhaill, R.E., Bouberhan, S., Hays, J.L., Wenham, R.M., Roque, D.R., Yeku, O.O., Liu, J.F., Wang, B., Yoo, S-Y., Govindraj, S., Zhu, M., Brouwer-Visser, J., Peterman, M.J., Barnes, B., Lowy, I., Knorr, D., Uldrick, T.S., Miller, E.A.
Published in Immuno-oncology technology (01.12.2023)
Published in Immuno-oncology technology (01.12.2023)
Get full text
Journal Article